Research programme: fixed dose combination therapies - Celator

Drug Profile

Research programme: fixed dose combination therapies - Celator

Alternative Names: AUY 922/docetaxel - Celator Pharma; CPX-571; Docetaxel/luminespib - Celator Pharma; Ipatasertib/selumetinib - Celator Pharma; Targeted cancer therapies: Celator Pharma

Latest Information Update: 11 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celator Pharmaceuticals
  • Class
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis modulators; DNA cross linking agents; DNA synthesis inhibitors; DNA topoisomerase I inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Histone acetyltransferase inhibitors; Histone deacetylase inhibitors; Mitogen-activated protein kinase kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors; Raf kinase inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Head and neck cancer; Lung cancer
  • Research Cancer

Most Recent Events

  • 10 Nov 2015 Preclinical data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC -2015)
  • 29 Oct 2015 Research programme: fixed dose combination therapies - Celator is available for licensing as of 29 Oct 2015. http://www.celatorpharma.com
  • 17 Jul 2014 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top